Intas Pharmaceuticals Ltd. (India) holds 44 active US FDA Type II Drug Master Files and 7 inactive, has DMF or CEP filings on record for 40 active ingredients, holds 1 active Type IV (excipient) Drug Master File and is linked to 4 FDA-registered manufacturing sites. 34 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Intas Pharmaceuticals Ltd.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/intas-pharmaceuticals-ltd

Overview

Intas Pharmaceuticals Ltd. is a leading Indian pharmaceutical company known for its extensive range of products spanning various therapeutic areas. The company is dedicated to providing affordable healthcare solutions with a strong focus on research and development.

Core services & business areas

Regulatory AffairsDistributionMarket Access

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Intas Pharmaceuticals Ltd. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Intas Pharmaceuticals Ltd. holds 44 active (51 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • LEVOTHYROXINE SODIUM USPActive2026-09-23
  • SODIUM OXYBATEActive2026-09-18
  • MYCOPHENOLATE SODIUM USPActive2026-09-18
  • 5-FLUOROURACIL USPActive2026-04-09
  • PALBOCICLIBActive2026-02-20
  • MYCOPHENOLATE MOFETIL USPActive2026-02-03
  • OLAPARIBActive2025-09-12
  • RUXOLITINIB PHOSPHATEActive2024-07-24
  • BENDAMUSTINE HYDROCHLORIDEActive2023-08-31
  • TOFACITINIB CITRATEActive2022-06-22
  • SODIUM THIOSULFATEActive2022-02-15
  • GEMCITABINE HYDROCHLORIDE USP (PROCESS-III)Active2021-12-24
  • PREGABALIN USP (PROCESS-II)Active2021-11-22
  • RIBOCICLIB SUCCINATEActive2021-09-30
  • PACLITAXEL (SEMI SYNTHETIC) USP (PROCESS-II)Active2021-09-02
  • DASATINIBActive2020-12-02
  • CARFILZOMIBActive2020-09-08
  • DIROXIMEL FUMARATEActive2020-03-27
  • DOXORUBICIN HYDROCHLORIDE USPActive2020-01-27
  • CARMUSTINE USPActive2019-03-26
  • TRIFLURIDINE USPActive2019-03-08
  • CAPECITABINE USP (PROCESS III)Active2019-03-04
  • TIPIRACIL HYDROCHLORIDEActive2019-02-19
  • DOFETILIDE USPActive2018-11-26
  • DIMETHYL FUMARATEActive2016-12-09
  • PERAMPANELActive2016-06-24
  • RIVAROXABAN FORM- I (MICRONIZED)Active2016-06-08
  • TERIFLUNOMIDEActive2016-04-21
  • DOCETAXEL ANHYDROUS USP (PROCESS II)Active2014-10-29
  • VILAZODONE HYDROCHLORIDE (AMORPHOUS)Active2014-10-10
  • LURASIDONE HYDROCHLORIDEActive2014-07-09
  • FINGOLIMOD HYDROCHLORIDE (FORM 1)Active2014-06-24
  • CABAZITAXEL (AMORPHOUS)Active2014-02-20
  • PREGABALINActive2014-01-06
  • DALFAMPRIDINEActive2013-12-30
  • AZACITIDINEActive2013-12-30
  • TRAZODONE HYDROCHLORIDE USP (PROCESS-II)Active2013-12-30
  • PRASUGREL HYDROCHLORIDEActive2013-06-27
  • PACLITAXEL USP (SEMI-SYNTHETIC)Active2013-01-17
  • LACOSAMIDEActive2012-10-19
  • FESOTERODINE FUMARATEActive2012-10-13
  • DECITABINEActive2011-09-21
  • CAPECITABINE USPActive2010-11-09
  • GEMCITABINE HYDROCHLORIDE USPActive2009-04-15
  • RELUGOLIXInactive2024-07-24
  • PAZOPANIB HYDROCHLORIDEInactive2020-03-23
  • IMATINIB MESYLATE (ß-FORM)Inactive2017-11-27
  • APREMILAST (AMORPHOUS)Inactive2017-10-23
  • ERLOTINIB HYDROCHLORIDEInactive2016-08-29
  • DABIGATRAN ETEXILATE MESYLATE FORM-IInactive2014-07-25

Showing the 50 most relevant of 51 Drug Master Files (active first). The full list is in the FDA DMF list.

Excipient Drug Master Files

Intas Pharmaceuticals Ltd. holds 1 active (1 total) FDA Type IV Drug Master File. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.

  • SODIUM CHOLESTERYL SULFATE FOR PHARMACEUTICAL USEActive2024-03-07

Registered manufacturing sites (4)

Physical sites registered with the US FDA and resolved to Intas Pharmaceuticals Ltd., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

34 FDA enforcement records linked to this company.

  • warning_letter2026-03-30

    FDA Warning Letter (drug product)

  • warning_letter2023-11-21

    FDA Warning Letter (drug product)

  • warning_letter2023-07-28

    FDA Warning Letter (drug product)

  • 4832022-12-02

    Procedures not in writing, fully followed

  • 4832022-12-02

    Test methods

  • 4832022-12-02

    Following/documenting laboratory controls

  • 4832022-12-02

    Complete test data included in records

  • 4832022-12-02

    Investigations of discrepancies, failures

  • 4832022-12-02

    Procedures for sterile drug products

  • 4832022-12-02

    Results not used for expiration dates, storage cond.

  • 4832022-12-02

    Extent of discrepancy, failure investigations

  • 4832022-12-02

    Absence of Written Procedures

  • 4832022-12-02

    Environmental Monitoring System

  • 4832022-12-02

    Computer control of master formula records

  • 4832019-08-02

    Scientifically sound laboratory controls

  • 4832019-08-02

    Air Supply

  • 4832019-08-02

    Air recirculation of dust from production areas

  • 4832019-08-02

    Procedure Deviations Recorded and Justified

  • 4832019-08-02

    Equipment for Environmental Control

  • 4832019-08-02

    Procedures for sterile drug products

  • 4832019-08-02

    Procedures not in writing, fully followed

  • 4832019-08-02

    Environmental Monitoring System

  • 4832019-08-02

    Absence of Written Procedures

  • 4832019-08-02

    Equipment Design, Size and Location

  • 4832019-08-02

    Establishment of calibration procedures

  • 4832019-08-02

    Validation lacking for sterile drug products

  • 4832019-08-02

    Suitability of testing methods verified

  • 4832019-08-02

    Written procedures fail to include

  • 4832018-06-08

    Investigations of discrepancies, failures

  • 4832018-06-08

    Environmental Monitoring System

  • 4832016-10-19

    Calibration/Inspection/Checking not done

  • 4832016-10-19

    Validation lacking for sterile drug products

  • 4832016-10-19

    Scientifically sound laboratory controls

  • 4832016-10-19

    Training , Education , Experience overall

For suppliers

Is this Intas Pharmaceuticals Ltd.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.